Live from the NIH registry
Studies recruiting near Little Rock right now
Top 25 of 509 recruiting studies, sorted by proximity — each links to its official registry page
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
B Acute Lymphoblastic Leukemia
Phase 2
Interventional 222 participants sought
Arkansas Children's Hospital — Little Rock, Arkansas (4.1 mi)
· Sponsor: National Cancer Institute (NCI)
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Non-Small Cell Lung Cancer
Phase 3
Interventional 675 participants sought
Research Site — Little Rock, Arkansas (4.1 mi)
· Sponsor: AstraZeneca
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
Cognitive Impairment Associated With Schizophrenia (CIAS)
Phase 2
Interventional 150 participants sought
Woodland International Research Group — Little Rock, Arkansas (4.1 mi)
· Sponsor: Kynexis B.V.
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
N/A
Interventional 400 participants sought
Medical Investigations — Little Rock, Arkansas (4.1 mi)
· Sponsor: Medtronic MiniMed, Inc.
We-Move With Windy: Gross Motor Development for Early Childhood
Physical Activities
N/A
Interventional 266 participants sought
Arkansas Children's Research Institute — Little Rock, Arkansas (4.1 mi)
· Sponsor: Arkansas Children's Hospital Research Institute
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer
Borderline Resectable/Unresectable Pancreatic Cancer, Non Metastatic Pancreatic Cancer
Phase 1, Phase 2
Interventional 20 participants sought
University of Arkansas for Medical Sciences — Little Rock, Arkansas (4.1 mi)
· Sponsor: University of Arkansas
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
Phase 2, Phase 3
Interventional 10,000 participants sought
University of Arkansas for Medical Sciences — Little Rock, Arkansas (4.1 mi)
· Sponsor: SWOG Cancer Research Network
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
High-grade Glioma, Solid Tumor, Unspecified, Child
Phase 1, Phase 2
Interventional 28 participants sought
Arkansas Children's Research Institute — Little Rock, Arkansas (4.1 mi)
· Sponsor: Laminar Pharmaceuticals
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
Aortoiliac Occlusive Disease, Peripheral Arterial Disease
N/A
Interventional 244 participants sought
Central Arkansas Veterans Healthcare System — Little Rock, Arkansas (4.1 mi)
· Sponsor: W.L.Gore & Associates
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma
Phase 2
Interventional 90 participants sought
Arkansas Children's Hospital — Little Rock, Arkansas (4.1 mi)
· Sponsor: Carl Allen
Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age
Lymphatic Malformation
Phase 2
Interventional 38 participants sought
Arkansas Children's Hospital/UAMS — Little Rock, Arkansas (4.1 mi)
· Sponsor: Protara Therapeutics
Juveena Hydrogel System Feasibility Study for Heavy Menstrual Bleeding (HMB)
Heavy Menstrual Bleeding
N/A
Interventional 7 participants sought
Applied Research Center of Arkansas — Little Rock, Arkansas (4.1 mi)
· Sponsor: Rejoni Inc.
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Major Depressive Disorder
Phase 3
Interventional 200 participants sought
Neurocrine Clinical Site — Little Rock, Arkansas (4.1 mi)
· Sponsor: Neurocrine Biosciences
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
Phase 3
Interventional 420 participants sought
Preferred Research Partners /ID# 270389 — Little Rock, Arkansas (4.1 mi)
· Sponsor: AbbVie
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Large B-cell Lymphoma, Lymphoma, B-Cell
Phase 3
Interventional 400 participants sought
University of Arkansas — Little Rock, Arkansas (4.1 mi)
· Sponsor: Lyell Immunopharma, Inc.
Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy
Endocervical Cancer
N/A
Interventional 20 participants sought
University of Arkansas for Medical Sciences — Little Rock, Arkansas (4.1 mi)
· Sponsor: University of Arkansas
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
Coronary Artery Disease
N/A
Interventional 310 participants sought
Arkansas Cardiology, P.A. — Little Rock, Arkansas (4.1 mi)
· Sponsor: Kardion Inc
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Platinum-resistant Ovarian Cancer, Testicular Cancer
Phase 1
Interventional 156 participants sought
University of Arkansas Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas (4.1 mi)
· Sponsor: Context Therapeutics Inc.
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
Cystic Fibrosis, CFTR Gene Mutation
Phase 2
Interventional 33 participants sought
University of Arkansas for Medical Sciences — Little Rock, Arkansas (4.1 mi)
· Sponsor: Arcturus Therapeutics, Inc.
E-Mindfulness Approaches for Living After Breast Cancer
Breast Cancer, Depression
Phase 3
Interventional 402 participants sought
University of Arkansas for Medical Sciences — Little Rock, Arkansas (4.1 mi)
· Sponsor: NRG Oncology
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Percutaneous Coronary Intervention, Peripheral Endovascular Intervention
Phase 4
Interventional 6,000 participants sought
Arkansas Cardiology — Little Rock, Arkansas (4.1 mi)
· Sponsor: Duke University
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
Neurogenic Detrusor Overactivity
Phase 2, Phase 3
Interventional 71 participants sought
Arkansas Childrens Hospital — Little Rock, Arkansas (4.1 mi)
· Sponsor: Urovant Sciences GmbH
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Low Grade Serous Ovarian Cancer
Phase 3
Interventional 270 participants sought
University of Arkansas — Little Rock, Arkansas (4.1 mi)
· Sponsor: Verastem, Inc.
Smart Checklist Implementation for Pediatric Tracheal Intubations in the ICU- Multicenter Study
Intubation Complication
N/A
Interventional 3,000 participants sought
University of Arkansas — Little Rock, Arkansas (4.1 mi)
· Sponsor: Children's Hospital of Philadelphia
A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures
Epilepsy, Generalized, Epilepsy, Absence
Phase 2
Interventional 12 participants sought
Clinical Trials, Inc. (CTI) — Little Rock, Arkansas (4.1 mi)
· Sponsor: NeuroPro Therapeutics, Inc.